The deals with Covance, NeoGenomics Laboratories, and Navigate BioPharma Services aim to expand access to NanoString's PanCancer IO 360 Gene Expression Panel.
The company, which previously focused on the development of multiplex PCR assays, is hoping to make its ATOM-seq technology available for research use later this year.
The team's Pro-Code system enabled simultaneous high-dimensional protein-level phenotyping of hundreds of genes with single-cell resolution.
The companies will work on applying barcoding technology to single-cell measurements of gene and protein expression and to immune cell profiling.
By using array-synthesized guide-donor oligonucleotide pairs, the team's gene editing technique allows accurate and detectable phenotyping in yeast cells.
The team plans to eventually implement the MSI test clinically to determine whether patients are eligible for immunotherapy.
The planned instrument will help provide spatial information on both protein and RNA in tumor samples and will be powered by nCounter technology.
The chemistry will be single-molecule, based on hybridization, and will not require amplification, enzymes, or library prep, the firm said.
The company launched the BD FACSseq flow cytometer and BD Precise Assays for high-throughput single-cell gene-expression analysis studies at the ASHG annual meeting.
The solutions will combine RainDance's digital droplet technology and single-molecule barcoding technology with PacBio's proprietary long-range DNA amplification technology.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.